MIR17: A Potential Drug Target for Cancer (G406952)
MIR17: A Potential Drug Target for Cancer
MIR17 (hsa-mir-17), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker. The discovery of MIR17 comes from a study conducted by a team of researchers at the University of California, San Diego School of Medicine.
The study, which was published in the journal Nature Medicine, identified MIR17 as a key regulator of the cell cycle, a process that helps cells grow, divide, and prepare for cell death. The researchers found that MIR17 was highly expressed in various types of cancer, including breast, ovarian, and prostate cancer.
Furthermore, the researchers found that MIR17 was associated with the development and progression of cancer. In particular, they found that MIR17 was highly expressed in human tissue samples that had been derived from patients with various types of cancer.
The researchers also found that MIR17 was associated with the failure of cancer therapies. They observed that MIR17 was highly expressed in the tissues of patients who had undergone cancer treatment and had a poor response to those treatments.
Based on these findings, the researchers concluded that MIR17 may be a useful drug target or biomarker for cancer therapies. They suggest that MIR17 may be a good target for drugs that can inhibit its activity, leading to the closure of the cell cycle and the inhibition of cancer cell growth.
The researchers also suggest that MIR17 may be a good biomarker for cancer, as its expression is associated with the development and progression of cancer. They plan to further investigate the potential of MIR17 as a drug target or biomarker for cancer therapies.
In conclusion, the discovery of MIR17 as a potential drug target or biomarker for cancer therapies has significant implications for the treatment of cancer. Further research is needed to fully understand its potential and to develop safe and effective drugs that can inhibit its activity.
Protein Name: MicroRNA 17
The "MIR17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR17 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222
